Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment

Luca Antonioli; Corrado Blandizzi; Fabio Malavasi; Davide Ferrari; György Haskó

doi:10.1080/2162402X.2016.1216292

Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment

Oncoimmunology. 2016 Jul 29;5(9):e1216292. doi: 10.1080/2162402X.2016.1216292. eCollection 2016.

Authors

Luca Antonioli¹, Corrado Blandizzi², Fabio Malavasi³, Davide Ferrari⁴, György Haskó⁵

Affiliations

¹ Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; Department of Surgery and Center for Immunity and Inflammation, Rutgers-New Jersey Medical School, Newark, NJ, USA.
² Department of Clinical and Experimental Medicine, University of Pisa , Pisa, Italy.
³ Laboratory of Immunogenetics and CeRMS, Department of Medical Sciences, University of Torino and Transplant Immunology, Città della Salute e della Scienza , Torino, Italy.
⁴ Department of Life Science and Biotechnology, University of Ferrara , Ferrara, Italy.
⁵ Department of Surgery and Center for Immunity and Inflammation, Rutgers-New Jersey Medical School , Newark, NJ, USA.

Abstract

The ecto-5'-nucleotidase/CD73 enzyme plays a pivotal role in generating an adenosine-enriched immunosuppressed and pro-angiogenic niche supporting cancer development. The targeting of CD73 leads to reorganization of tumor microenvironment, shaping the phenotype of the infiltrating T cells. The development of CD73 monoclonal antibodies offers a promising new avenue for antineoplastic treatment.

Keywords: CD73; autophagy; immunotherapy; monoclonal antibody; tumor microenvironment.

Publication types

Editorial